Plasma Cyclophilin A as a Novel Biomarker in Chronic Nephropathy

Main Article Content

Mohy Eldin Abd EL-Fattah
Taghrid B. El-abaseri
Hegazy Mohamed Abd Elaziz Mohamed


Background: Type 2 diabetes mellitus (DM) is the most common cause of end- stage renal disease. Albuminuria is the foremost commonly utilized marker to anticipate onset of diabetic nephropathy (DN) without sufficient affectability and specificity to identify early DN.

Aim: This study aimed to evaluate Plasma cyclophilin A (CypA) as a new biomarker for early DN.

Methods: This cross sectional study included 125 Egyptian subjects attending the out Patients Clinic of the Department of Internal Medicine, 10Th of Ramadan city Health Insurance Hospital and divided into-:control group, patient with diabetic mellitus, patients with Diabetic nephropathy and patient with diabetic nephropathy and other complications. Patients were subjected to measurement of plasma cyclophyline A, FBS, HbAIC, serum creatinine, serum urea, serum uric acid, k, Na, serum phosphorus, Albumin:Creatinine Ratio, GFR, Chol, TG, LDL HDL, AST, ALT, T.BIL, D.BIL ALB, TP, GLB and A/G ratio.

Results: Results showed that Cyclophilin A was significantly correlated with duration of DM, CR, Urea, UR.A, Na, phosphorus, ACR, Chol, TG, LDL, AST, ALT, T.BIL, D.BIL. Meanwhile, Cyclophilin A was negatively correlated with HA1C, K, GFR, HDL, ALB, TP, GLB and A/G ratio. At cut-off level ≥84.14, cyclophilin A had 91% sensitivity and 62% specificity for diagnosing diabetic nephropathy.

Conclusion: CypA can be used as an early marker for DN as we found early significant high levels of urinary CypA in diabetic patients with stage 2 DN even before the appearance of albuminuria.

Plasma cyclophilin A, DN

Article Details

How to Cite
EL-Fattah, M. E. A., El-abaseri, T. B., & Mohamed, H. M. A. E. (2020). Plasma Cyclophilin A as a Novel Biomarker in Chronic Nephropathy. International Journal of Biochemistry Research & Review, 29(10), 63-72.
Original Research Article


Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med. 2001;345:910–912.

Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update. Vascul Pharmacol. 2013;58:259–271.

Halimi JM. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab. 2012;38:291–297.

Tramonti G, Kanwar YS. Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy. Endocrine 2013;43:494–503.

Kramer HJ, Nguyen QD, Curhan G et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273–3277.

MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27:195–200.

Kamijo-Ikemori A, Sugaya T, Kimura K. Novel urinary biomarkers in early diabetic kidney disease. Curr Diabetes Rep. 2014;14:513.

Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 2014;63(2 Suppl 2):S39– S62.

Titan SM, Zatz R, Graciolli FG, et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol. 2011;6:241–247.

Nielsen SE, Andersen S, Zdunek D et al. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int. 2011;79:1113–1118.

Tramonti G, Kanwar YS. Tubular biomarkers to assess progression of diabetic nephropathy. Kidney Int. 2011;79:1042–1044.

Wolkow PP, Niewczas MA, Perkins B et al. Association of urinary inflammatory markers and renal decline in micro albuminuric type 1 diabetics. J Am Soc Nephrol. 2008;19:789–797.

Hinokio Y, Suzuki S, Hirai M et al. Urinary excretion of 8- oxo-7, 8-dihydro-2′- deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia. 2002;45:877–882.

Krolewski AS, Warram JH, Forsblom C et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Care. 2012;35:2311–2316.

Satoh K, Shimokawa H, Berk BC, Cyclophilin A. Promising new target in cardiovascular therapy. Circ J. 2010;74:2249–2256.

Nigro P, Pompilio G, Capogrossi MC. Cyclophilin A: A key player for human disease. Cell Death Dis 2013;4:e888.

Ramachandran S, Venugopal A, Kutty VR et al. Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. Cardiovasc Diabetol. 2014;13:38.

Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM et al. Diabetic kidney disease: From physiology to therapeutics. J. Physiol. 2014;592:3997

Amer Hanan, Mohamed Ali et al. The role of urinary cyclophilin A as a new marker for diabetic nephropathy.The Egyptian Journal of Hospital Medicine. 2018;70(9):1431- 1439.

Tsai S, Su CW, Wu MJ et al. Urinary Cyclophilin A as a New Marker for Diabetic Nephropathy A Cross-Sectional Analysis of Diabetes Mellitus. Medicine. 2015;94(42):e1802.

Ramachandran S, Venugopal A, Kutty VR et al. Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. Cardiovascular Diabetology. 2014;13:38.

Zachwieja J, Soltysiak J, Fichna P et al. Normal-range albuminuria does not exclude nephropathy in diabetic children. Pediatr Nephrol. 2010;25:1445–1451.